Jpmorgan Chase & CO Gain Therapeutics, Inc. Transaction History
Jpmorgan Chase & CO
- $1.51 Trillion
- Q3 2025
A detailed history of Jpmorgan Chase & CO transactions in Gain Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 26,280 shares of GANX stock, worth $74,372. This represents 0.0% of its overall portfolio holdings.
Number of Shares
26,280
Previous 26,280
-0.0%
Holding current value
$74,372
Previous $46,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding GANX
# of Institutions
42Shares Held
5.02MCall Options Held
10.3KPut Options Held
0-
Jones Financial Companies Lllp677KShares$1.92 Million0.0% of portfolio
-
David Einhorn Greenlight Capital Inc | New York, Ny588KShares$1.67 Million0.1% of portfolio
-
Dme Capital Management, LP New York, NY566KShares$1.6 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA534KShares$1.51 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il374KShares$1.06 Million0.0% of portfolio
About Gain Therapeutics, Inc.
- Ticker GANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,883,400
- Market Cap $33.6M
- Description
- Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietar...